Abadijoo Hamed, Khayamian Mohammad Ali, Faramarzpour Mahsa, Ghaderinia Mohammadreza, Simaee Hossein, Shalileh Shahriar, Yazdanparast Seyed Mojtaba, Ghabraie Bahman, Makarem Jalil, Sarrami-Forooshani Ramin, Abdolahad Mohammad
Nano Electronic Center of Excellence, Nano Bio Electronic Devices Lab, School of Electrical and Computer Engineering, University of Tehran, Tehran, Iran.
Nano Electronic Center of Excellence, Thin Film and Nano Electronics Lab, School of Electrical and Computer Engineering, University of Tehran, Tehran, Iran.
Front Bioeng Biotechnol. 2022 Jun 2;10:850571. doi: 10.3389/fbioe.2022.850571. eCollection 2022.
In the case of the COVID-19 early diagnosis, numerous tech innovations have been introduced, and many are currently employed worldwide. But, all of the medical procedures for the treatment of this disease, up to now, are just limited to chemical drugs. All of the scientists believe that the major challenge toward the mortality of the COVID-19 patients is the out-of-control immune system activation and the subsequent cytokine production. During this process, the adaptive immune system is highly activated, and many of the lymphocytes start to clonally expand; hence many cytokines are also released. So, any attempt to harness this cytokine storm and calm down the immune outrage is appreciated. While the battleground for the immune hyperactivation is the lung ambient of the infected patients, the only medical treatment for suppressing the hypercytokinemia is based on the immunosuppressor drugs that systemically dampen the immunity with many unavoidable side effects. Here, we applied the alternating electric field to suppress the expansion of the highly activated lymphocytes, and by reducing the number of the renewed cells, the produced cytokines were also decreased. Applying this method to the blood of the COVID-19 patients showed ∼33% reduction in the average concentration of the three main cytokines after 4 days of stimulation. This method could carefully be utilized to locally suppress the hyperactivated immune cells in the lung of the COVID-19 patients without any need for systemic suppression of the immune system by the chemical drugs.
在新冠病毒早期诊断方面,已经引入了众多技术创新,其中许多目前正在全球范围内应用。但是,截至目前,治疗这种疾病的所有医疗程序都仅限于化学药物。所有科学家都认为,新冠病毒患者死亡的主要挑战在于失控的免疫系统激活以及随后的细胞因子产生。在此过程中,适应性免疫系统被高度激活,许多淋巴细胞开始克隆性扩增;因此也会释放许多细胞因子。所以,任何控制这种细胞因子风暴并平息免疫过激反应的尝试都是值得赞赏的。虽然免疫过度激活的战场是感染患者的肺部环境,但抑制高细胞因子血症的唯一医学治疗方法是基于免疫抑制药物,这些药物会系统性地抑制免疫力,且伴有许多不可避免的副作用。在此,我们应用交变电场来抑制高度激活的淋巴细胞的扩增,通过减少更新细胞的数量,所产生的细胞因子也会减少。将这种方法应用于新冠病毒患者的血液中,在刺激4天后,三种主要细胞因子的平均浓度降低了约33%。这种方法可以谨慎地用于局部抑制新冠病毒患者肺部过度激活的免疫细胞,而无需用化学药物对免疫系统进行全身抑制。